Understanding Contraindications for Austedo Medication Austedo (deutetrabenazine) is a medication prescribed to treat chorea associated with Huntington’s disease and tardive....

Understanding Contraindications for Austedo Medication

Austedo (deutetrabenazine) is a medication prescribed to treat chorea associated with Huntington’s disease and tardive dyskinesia. While it can be highly effective for specific neurological conditions, like all potent medications, Austedo has specific contraindications—conditions or factors that make its use inappropriate or potentially harmful. Understanding these contraindications is crucial for patient safety and effective treatment.

This article outlines six key contraindications for Austedo medication, providing essential information for patients, caregivers, and healthcare professionals. It is important to remember that this content is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis, treatment, and all medication-related decisions.

6 Key Contraindications for Austedo Medication

1. Severe Hepatic Impairment

Austedo is primarily metabolized in the liver, and patients with severe hepatic impairment (liver dysfunction) cannot process the medication effectively. This can lead to increased concentrations of the drug and its active metabolites in the body, significantly raising the risk of severe adverse effects. Therefore, Austedo is strictly contraindicated in individuals with severe liver disease to prevent potential toxicity and complications. Patients with moderate hepatic impairment may require dose adjustments and careful monitoring, but severe impairment necessitates complete avoidance.

2. Concomitant Use with Reserpine or Tetrabenazine

Austedo works by reversibly inhibiting vesicular monoamine transporter 2 (VMAT2). Other medications, such as reserpine and tetrabenazine (another VMAT2 inhibitor, brand name Xenazine), also affect VMAT2. Using Austedo concurrently with reserpine or tetrabenazine can lead to an additive effect of VMAT2 inhibition. This excessive inhibition can cause a profound depletion of monoamines, resulting in severe and potentially life-threatening adverse reactions, including parkinsonism, sedation, and hypotension. Due to this significant interaction risk, co-administration is strictly contraindicated.

3. Concomitant Use with Monoamine Oxidase Inhibitors (MAOIs)

Monoamine Oxidase Inhibitors (MAOIs) are a class of antidepressants that prevent the breakdown of monoamine neurotransmitters (like dopamine, norepinephrine, and serotonin) in the brain. Austedo also influences monoamine levels by inhibiting their storage. Combining Austedo with MAOIs can lead to dangerously high levels of these neurotransmitters, potentially causing severe and life-threatening reactions such as hypertensive crisis (a sudden, severe increase in blood pressure) or serotonin syndrome. For this reason, Austedo is contraindicated in patients taking MAOIs, and there should be at least a 14-day washout period after discontinuing an MAOI before initiating Austedo.

4. Patients with Suicidal Ideation or Untreated/Worsening Depression

Austedo carries a Boxed Warning regarding the risk of depression and suicidality, particularly in patients with Huntington’s disease. Patients who are already experiencing suicidal ideation, or have untreated or inadequately treated depression, are at an increased risk of worsening psychiatric symptoms when taking Austedo. In such cases, the risks often outweigh the potential benefits, making the medication contraindicated. Close monitoring for changes in mood, behavior, and the emergence of suicidal thoughts is critical for all patients, especially those with a history of psychiatric illness.

5. Hypersensitivity to Deutetrabenazine or Any Excipient

As with any medication, individuals who have a known hypersensitivity or allergic reaction to deutetrabenazine (the active ingredient in Austedo) or any of its inactive components (excipients) should not use the drug. Hypersensitivity reactions can range from mild skin rashes to severe anaphylaxis, which is a life-threatening allergic response. Before starting Austedo, healthcare providers should inquire about any known allergies to avoid such reactions.

6. History of Neuroleptic Malignant Syndrome (NMS) or Tardive Dyskinesia-Related Adverse Events with VMAT2 Inhibitors

Austedo can potentially cause Neuroleptic Malignant Syndrome (NMS), a rare but serious and potentially fatal neurological disorder characterized by fever, muscle rigidity, altered mental status, and autonomic instability. While NMS is a possible side effect, a history of NMS specifically related to previous VMAT2 inhibitor treatment (like tetrabenazine) is a strong contraindication for re-initiating Austedo. Similarly, severe adverse events related to tardive dyskinesia that occurred with other VMAT2 inhibitors may also warrant caution or contraindication, as they indicate a heightened individual susceptibility to severe reactions to this class of drugs.

Summary

Austedo is a valuable medication for managing specific movement disorders, but its use requires careful consideration of potential risks. The contraindications discussed—including severe hepatic impairment, concomitant use with reserpine, tetrabenazine, or MAOIs, existing suicidal ideation or untreated depression, hypersensitivity, and a history of NMS with VMAT2 inhibitors—are critical factors that healthcare providers must evaluate. Adhering to these guidelines helps ensure the safe and effective use of Austedo, minimizing the potential for severe adverse reactions. Always discuss your full medical history and all current medications with your doctor before starting any new treatment.